Clinical trial
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC)…
NCT00138060 · Institut de Recherche Clinique sur les Cancers et le Sang, Other · Completed
Key facts
| NCT number | NCT00138060 |
|---|---|
| Title | Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants |
| Official title | Protocole Evaluant Chez Des Patients Porteurs de Cancers Colorectaux Metastatiques l'Interet Des Determinants Genotypiques Pour l'Optimisation de l'Efficacite et de la Tolerance de la Chimiotherapie Par Irinotecan et 5-fluorouracile |
| Lead sponsor | Institut de Recherche Clinique sur les Cancers et le Sang, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | irinotecan, 5 fluorouracil |
| Enrollment | 71 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 30, 2005 |
| Last update posted | Jul 20, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: